Skip to main content
Egyptian Rheumatology and Rehabilitation
Download PDF
  • Original article
  • Open access
  • Published:

Synovial fluid anti-citrulline-containing peptide antibody and its role in the diagnosis of rheumatoid arthritis

Egyptian Rheumatology and Rehabilitation volume 44, pages 97–102 (2017)Cite this article

Abstract

Objective

This study aimed to measure the level of anti-citrulline-containing peptide (anti-CCP) antibody (ab) in the synovial fluid (SF) of rheumatoid arthritis (RA) patients to study its relations with anti-CCP ab serum level, RA disease activity, and severity parameters as well as to explore its diagnostic value in RA.

Patients and methods

This study was conducted on 60 RA and 60 osteoarthritis (OA) patients. Patients were subjected to thorough history taking and full clinical examination including locomotor system examination. The Health Assessment Questionnaire was used for the assessment of functional capacity. Complete laboratory investigations including a complete blood count, erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, serum and SF anti-CCP ab levels were carried out. The Sharp score was calculated for the assessment of RA severity in posteroanterior plain radiographic views of both hands and feet.

Results

The mean SF anti-CCP ab level was highly significantly increased (P=0.0001) in RA patients (133.93±41.3 ng/l) in comparison with OA patients (5±13.2 ng/l). There were statistically significant correlations of SF anti-CCP ab level with rheumatoid factor (P=0.049), serum anti-CCP ab (P=0.0001), and Sharp score (P=0.037), whereas other clinical and laboratory parameters did not show any significant correlation (P>0.05). The specificity of SF anti-CCP ab and serum anti-CCP ab of RA patients was 100%. Besides, the sensitivity of serum anti-CCP ab was 90%, whereas the sensitivity of SF anti-CCP ab was 83.3%. The positive predictive value of both serum and SF anti-CCP abs was 100% in RA patients and their negative predictive value was 90.9% in the serum of RA patients and 85.7% in the SF. The cutoff value of anti-CCP ab was 65.4 ng/l in the serum and 63.35 ng/l in the SF.

Conclusion

SF anti-CCP ab is significantly increased in RA compared with OA and could be considered an appreciated diagnostic marker having a major role in the identification of RA patients not fulfilling the criteria for the RA disease diagnosis. Its relation to RA disease severity could not be established.

References

  1. Roberts CA, Dickinson AK, Taams LS. The interplay between monocytes/macrophages and CD4+ T cell subsets in rheumatoid arthritis. Front Immunol 2015; 6:571–579

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ding J, Eyre S, Worthington J. Genetics of RA susceptibility, what comes next? RMD Open 2015; 1:28–33

    Article  Google Scholar 

  3. Iain B, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205–2219

    Article  Google Scholar 

  4. Kapitany A, Szabo Z, Lakos G, Aleksza M, Végvari A. Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. Isr Med Assoc J 2008; 10:32–36

    PubMed  Google Scholar 

  5. Shibahara T, Matsushita T, Matsuo R, Fukushima Y, Fukuda K, Sugimori H, et al. Anti-cyclic citrullinated peptide antibody-positive meningoencephalitis in the preclinical period of rheumatoid arthritis. Case Rep Neurol 2016; 8:156–160

    Article  PubMed  PubMed Central  Google Scholar 

  6. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–2581

    Article  PubMed  Google Scholar 

  7. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039–1049

    CAS  PubMed  Google Scholar 

  8. Prevoo ML, Van’t Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel P. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–48

    CAS  Google Scholar 

  9. Van der Heidje D, Dankert T, Neiman DF, Rau R, Boers M. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38:941–947

    Article  Google Scholar 

  10. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002; 4:265–272

    Article  Google Scholar 

  11. Liu D, Guo M, Yun M, Jiao Y, Zhang J, Luo Y, et al. Diagnostic value of serum and joint fluid anti-CCP (citrulline-containing peptide) antibody for rheumatoid arthritis and its relationship with other inflammatory indicators. Sci Res Essays 2011; 6:2465–2469

    CAS  Google Scholar 

  12. Mimori T. Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Int Med 2005; 44:1122–1129

    Article  CAS  Google Scholar 

  13. Fernandes-Cerqueira C, Ossipova E, Gunasekera S, Hansson M, Mathsson L, Catrina A, et al. Targeting of anti-citrullinated protein/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens. Arthritis Res Ther 2015; 17:155–200

    Article  PubMed  PubMed Central  Google Scholar 

  14. Spadaro A, Riccieri V, Scrivo R, Alessandri C, Valesini G. Anti-cyclic citrullinated peptide antibody determination in synovial fluid of psoriatic arthritis. Clin Exp Rheumatol 2007; 25:599–604

    CAS  PubMed  Google Scholar 

  15. Caspi D, Anouk M, Golan I, Paran D, Kantman I, Wigler I.Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2006; 55:53–56

    Article  CAS  PubMed  Google Scholar 

  16. Landmann T, Kehl G, Bergner R. The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis. Clin Rheumatol 2010; 29:1449–1453

    Article  PubMed  Google Scholar 

  17. Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in a clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63:1090–1095

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Münevver Serdaroglu, Hasim Çakırbay, Orhan Değer, Sevil Cengiz, Sibel Kul. The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2493537/RheumatolInt 2008; 28:965–970

    Google Scholar 

  19. Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M. The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis. Mikrobiyol Bul 2008; 42:669–674

    PubMed  Google Scholar 

  20. Porto LS, Tavares Júnior WC,Costa DA, Lanna CC, Kakehasi AM. Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a magnetic resonance imaging study. Rev Bras Rheumatol 2015; 57:15–22

    Article  Google Scholar 

  21. NehirSamanci,OzdemS,AkbasH,MutluD,GultekinM,ArmanM,DonmezL. Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis. J Net Med Assoc 2005; 97:1120–1126

    Google Scholar 

  22. Irandokht Shenavr Masooleh, Asghar Hajiabbasi, Habib Zayeni, Atefeh Ghanbari, Habib Zayeni, Violet Zaker EStegghamat, et al. Anticyclic citrullinated peptide antibody in rheumatoid arthritis: a cross-sectional study in Iran. Turk J Med Sci 2016; 46:1309–1310

    Article  Google Scholar 

  23. Kim DA, Kim TY. RF vs. anti-CCP: competitor or companion? Rheumatol Int 2011; 31:1257–1258

    Article  PubMed  Google Scholar 

  24. Li T, Bao J, Yin J, Xu HJ. The specificity of anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis from a large cohort study in the Chinese. Zhonghua Nei Ke Za Zhi 2011; 91:1633–1636

    Google Scholar 

  25. Guler H, Turhanoglu AD, Ozer B, Ozer C, Balci A. The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis. Scand J Rheumatol 2008; 37:337–342

    Article  CAS  PubMed  Google Scholar 

  26. Laura Gonzalez-Lopez, Rocha-Muñoz A, Ponce-Guarneros M, Flores-Chavez A, Salazar-Paramo M, Nava A, et al. Anti-cyclic citrullinated peptide (Anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis. J Immunol Res 2014; 2014:536050

    Google Scholar 

  27. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004; 63:1085–1089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Samanci N, Ozdem S, Akbas H, Mutlu D, Gultekin M, Arman M, Donmez L. Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis. J Net Med Assoc 2005; 97:1120–1126

    Google Scholar 

  29. Heidari B, Heidari P, Hajian-Tilaki K, Firouzjahi AR. The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis - the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis. Ann Saudi Med 2010; 29:467–470

    Article  Google Scholar 

  30. Sockalingam S, Khuan CS, Sthaneshwar P. Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity. Int J Rheum Dis 2009; 12:211–215

    Article  PubMed  Google Scholar 

  31. Schellekens GA, Visser H, De Jong BA, Van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155–163

    Article  CAS  PubMed  Google Scholar 

  32. Hayashi N, Kumagai S. Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis [in Japanese]. Rinsho Byori 2010; 58:466–479

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Rehabilitation & Physical Medicine, Faculty of Medicine, Benha University, Benha, 13511, Egypt

    Ali I. Fouda, Nashwa I. Hashaad (MD) & Sabreen Hamza

  2. Department of Clinical Pathology, Faculty of Medicine, Benha University, Benha, Egypt

    Ibrahim Rageh

Authors
  1. Ali I. Fouda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ibrahim Rageh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nashwa I. Hashaad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabreen Hamza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nashwa I. Hashaad.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fouda, A.I., Rageh, I., Hashaad, N.I. et al. Synovial fluid anti-citrulline-containing peptide antibody and its role in the diagnosis of rheumatoid arthritis. Egypt Rheumatol Rehabil 44, 97–102 (2017). https://doi.org/10.4103/err.err_5_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/err.err_5_17

Keywords